Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- Author
- JACOBSON, Ira M1 ; DORE, Gregory J2 ; OUWERKERK-MAHADEVAN, Sivi10 ; DE LA ROSA, Guy11 ; KALMEIJER, Ronald11 ; SCOTT, Jane12 ; SINHA, Rekha9 ; BEUMONT-MAUVIEL, Maria9 ; FOSTER, Graham R3 ; FRIED, Michael W4 ; RADU, Monica5 ; RAFALSKY, Vladimir V6 ; MOROZ, Larysa7 ; CRAXI, Antonio8 ; PEETERS, Monika9 ; LENZ, Oliver9
[1] Weill Cornell Medical College, New York, NY, United States
[2] Kirby Institute, University of New South Wales, Darlinghurst, NSW, Australia
[3] Queen Mary, University of London, London, United Kingdom
[4] University of North Carolina at Chapel Hill, NC, United States
[5] Institutut de Boli Infectioase, Bucharest, Romania
[6] Smolensk Regional Clinical Hospital, Smolensk State Medical Academy, Smolensk Oblast, Russian Federation
[7] Vinnytsia National Medical University, Vinnytsia, Ukraine
[8] Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy
[9] Janssen Infectious Diseases, Beerse, Belgium
[10] Janssen Research and Development, Beerse, Belgium
[11] Janssen Research and Development, Titusville, NJ, United States
[12] Janssen Global Services, High Wycombe, United Kingdom - Source
Lancet (British edition). 2014, Vol 384, Num 9941, pp 403-413, 11 p ; ref : 38 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Anticancéreux Antiviral Association médicamenteuse Essai clinique Etude double insu Forme pégylée Génotype Homme Hépatite virale C Interféron alpha 2a Malade Médecine Phase Ribavirine Typage Essai randomisé contrôlé Traitement initial Analogue de nucléoside Cytokine Infection Pathologie de l'appareil digestif Pathologie du foie Virose
- Keyword (en)
- Antineoplastic agent Antiviral Drug combination Clinical trial Double blind study Pegylated form Genotype Human Viral hepatitis C Interferon alpha 2a Patient Medicine Phase Ribavirin Typing Randomized controlled trial Nucleoside analog Cytokine Infection Digestive diseases Hepatic disease Viral disease
- Keyword (es)
- Anticanceroso Antiviral Asociación medicamentosa Ensayo clínico Estudio doble ciego Forma pegilada Genotipo Hombre Hepatítis virica C Interferon alfa 2a Enfermo Medicina Fase Ribavirina Tipificación Ensayo aleatorio controlado Análogo nucleósido Citoquina Infección Aparato digestivo patología Hígado patología Virosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02G Viral hepatitis
- Discipline
- Generalities in medical sciences Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28680884
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(14)60494-3 
https://dx.doi.org/10.1016/S0140-6736(14)60494-3
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"384\";s:8:\"\u0000*\u0000issue\";s:4:\"9941\";s:8:\"\u0000*\u0000spage\";s:3:\"403\";s:8:\"\u0000*\u0000epage\";s:3:\"413\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"JACOBSON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ira M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:15:\"DORE, Gregory J\";i:1;s:25:\"OUWERKERK-MAHADEVAN, Sivi\";i:2;s:15:\"DE LA ROSA, Guy\";i:3;s:17:\"KALMEIJER, Ronald\";i:4;s:11:\"SCOTT, Jane\";i:5;s:12:\"SINHA, Rekha\";i:6;s:22:\"BEUMONT-MAUVIEL, Maria\";i:7;s:16:\"FOSTER, Graham R\";i:8;s:16:\"FRIED, Michael W\";i:9;s:12:\"RADU, Monica\";i:10;s:20:\"RAFALSKY, Vladimir V\";i:11;s:13:\"MOROZ, Larysa\";i:12;s:14:\"CRAXI, Antonio\";i:13;s:15:\"PEETERS, Monika\";i:14;s:12:\"LENZ, Oliver\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"384\";s:8:\"\u0000*\u0000issue\";s:4:\"9941\";s:8:\"\u0000*\u0000spage\";s:3:\"403\";s:8:\"\u0000*\u0000epage\";s:3:\"413\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"JACOBSON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ira M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:15:\"DORE, Gregory J\";i:1;s:25:\"OUWERKERK-MAHADEVAN, Sivi\";i:2;s:15:\"DE LA ROSA, Guy\";i:3;s:17:\"KALMEIJER, Ronald\";i:4;s:11:\"SCOTT, Jane\";i:5;s:12:\"SINHA, Rekha\";i:6;s:22:\"BEUMONT-MAUVIEL, Maria\";i:7;s:16:\"FOSTER, Graham R\";i:8;s:16:\"FRIED, Michael W\";i:9;s:12:\"RADU, Monica\";i:10;s:20:\"RAFALSKY, Vladimir V\";i:11;s:13:\"MOROZ, Larysa\";i:12;s:14:\"CRAXI, Antonio\";i:13;s:15:\"PEETERS, Monika\";i:14;s:12:\"LENZ, Oliver\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"384\";s:8:\"\u0000*\u0000issue\";s:4:\"9941\";s:8:\"\u0000*\u0000spage\";s:3:\"403\";s:8:\"\u0000*\u0000epage\";s:3:\"413\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"JACOBSON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ira M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:15:\"DORE, Gregory J\";i:1;s:25:\"OUWERKERK-MAHADEVAN, Sivi\";i:2;s:15:\"DE LA ROSA, Guy\";i:3;s:17:\"KALMEIJER, Ronald\";i:4;s:11:\"SCOTT, Jane\";i:5;s:12:\"SINHA, Rekha\";i:6;s:22:\"BEUMONT-MAUVIEL, Maria\";i:7;s:16:\"FOSTER, Graham R\";i:8;s:16:\"FRIED, Michael W\";i:9;s:12:\"RADU, Monica\";i:10;s:20:\"RAFALSKY, Vladimir V\";i:11;s:13:\"MOROZ, Larysa\";i:12;s:14:\"CRAXI, Antonio\";i:13;s:15:\"PEETERS, Monika\";i:14;s:12:\"LENZ, Oliver\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"384\";s:8:\"\u0000*\u0000issue\";s:4:\"9941\";s:8:\"\u0000*\u0000spage\";s:3:\"403\";s:8:\"\u0000*\u0000epage\";s:3:\"413\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"JACOBSON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ira M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:15:\"DORE, Gregory J\";i:1;s:25:\"OUWERKERK-MAHADEVAN, Sivi\";i:2;s:15:\"DE LA ROSA, Guy\";i:3;s:17:\"KALMEIJER, Ronald\";i:4;s:11:\"SCOTT, Jane\";i:5;s:12:\"SINHA, Rekha\";i:6;s:22:\"BEUMONT-MAUVIEL, Maria\";i:7;s:16:\"FOSTER, Graham R\";i:8;s:16:\"FRIED, Michael W\";i:9;s:12:\"RADU, Monica\";i:10;s:20:\"RAFALSKY, Vladimir V\";i:11;s:13:\"MOROZ, Larysa\";i:12;s:14:\"CRAXI, Antonio\";i:13;s:15:\"PEETERS, Monika\";i:14;s:12:\"LENZ, Oliver\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(14)60494-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"384\";s:8:\"\u0000*\u0000issue\";s:4:\"9941\";s:8:\"\u0000*\u0000spage\";s:3:\"403\";s:8:\"\u0000*\u0000epage\";s:3:\"413\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"JACOBSON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ira M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:15:\"DORE, Gregory J\";i:1;s:25:\"OUWERKERK-MAHADEVAN, Sivi\";i:2;s:15:\"DE LA ROSA, Guy\";i:3;s:17:\"KALMEIJER, Ronald\";i:4;s:11:\"SCOTT, Jane\";i:5;s:12:\"SINHA, Rekha\";i:6;s:22:\"BEUMONT-MAUVIEL, Maria\";i:7;s:16:\"FOSTER, Graham R\";i:8;s:16:\"FRIED, Michael W\";i:9;s:12:\"RADU, Monica\";i:10;s:20:\"RAFALSKY, Vladimir V\";i:11;s:13:\"MOROZ, Larysa\";i:12;s:14:\"CRAXI, Antonio\";i:13;s:15:\"PEETERS, Monika\";i:14;s:12:\"LENZ, Oliver\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
